Abstract
Objective. Leukemia is a cancer of the blood cells. Leukemic THP-1 and U937 cells were used in this study as monocytic effectors cells for proliferation responses and macrophage-like cells induction in leukemia. Pardaxin is an antimicrobial peptide isolated from the marine fish species. Methods. After treatment for 5 days, pardaxin significantly suppressed cell viability and arrested cell cycle at G0/G1 phase in leukemic cells which were evaluated. Results. Pardaxin also induced cell differentiation and maturation of THP-1 and U937 cells into macrophage-like cells with phagocytotic ability. Moreover, pardaxin elevated the expression of MyD88 but not toll-like receptor (TLR)-2 in both leukemic cells. TLR-2 blocking peptide was used to confirm that pardaxin attenuated phagocytotic ability and superoxide anion production in leukemic cells via activating MyD88 protein. Conclusions. These findings suggested that pardaxin has a therapeutic potential for leukemia.
| Original language | English |
|---|---|
| Article number | 7035087 |
| Journal | Evidence-based Complementary and Alternative Medicine |
| Volume | 2019 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Complementary and alternative medicine
Cite this
Pardaxin Promoted Differentiation and Maturation of Leukemic Cells via Regulating TLR2/MyD88 Signal against Cell Proliferation. / Uen, Wu Ching; Choong, Chen Yen; Tai, Chen Jei; Tai, Cheng Jeng.
In: Evidence-based Complementary and Alternative Medicine, Vol. 2019, 7035087, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pardaxin Promoted Differentiation and Maturation of Leukemic Cells via Regulating TLR2/MyD88 Signal against Cell Proliferation
AU - Uen, Wu Ching
AU - Choong, Chen Yen
AU - Tai, Chen Jei
AU - Tai, Cheng Jeng
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objective. Leukemia is a cancer of the blood cells. Leukemic THP-1 and U937 cells were used in this study as monocytic effectors cells for proliferation responses and macrophage-like cells induction in leukemia. Pardaxin is an antimicrobial peptide isolated from the marine fish species. Methods. After treatment for 5 days, pardaxin significantly suppressed cell viability and arrested cell cycle at G0/G1 phase in leukemic cells which were evaluated. Results. Pardaxin also induced cell differentiation and maturation of THP-1 and U937 cells into macrophage-like cells with phagocytotic ability. Moreover, pardaxin elevated the expression of MyD88 but not toll-like receptor (TLR)-2 in both leukemic cells. TLR-2 blocking peptide was used to confirm that pardaxin attenuated phagocytotic ability and superoxide anion production in leukemic cells via activating MyD88 protein. Conclusions. These findings suggested that pardaxin has a therapeutic potential for leukemia.
AB - Objective. Leukemia is a cancer of the blood cells. Leukemic THP-1 and U937 cells were used in this study as monocytic effectors cells for proliferation responses and macrophage-like cells induction in leukemia. Pardaxin is an antimicrobial peptide isolated from the marine fish species. Methods. After treatment for 5 days, pardaxin significantly suppressed cell viability and arrested cell cycle at G0/G1 phase in leukemic cells which were evaluated. Results. Pardaxin also induced cell differentiation and maturation of THP-1 and U937 cells into macrophage-like cells with phagocytotic ability. Moreover, pardaxin elevated the expression of MyD88 but not toll-like receptor (TLR)-2 in both leukemic cells. TLR-2 blocking peptide was used to confirm that pardaxin attenuated phagocytotic ability and superoxide anion production in leukemic cells via activating MyD88 protein. Conclusions. These findings suggested that pardaxin has a therapeutic potential for leukemia.
UR - http://www.scopus.com/inward/record.url?scp=85062788384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062788384&partnerID=8YFLogxK
U2 - 10.1155/2019/7035087
DO - 10.1155/2019/7035087
M3 - Article
AN - SCOPUS:85062788384
VL - 2019
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
SN - 1741-427X
M1 - 7035087
ER -